Russian Heart Failure Journal 2010year Pentoxifylline’s effect on myocardial viability in patients with chronic heart failure according to results of dobutamine stress echocardiography

To access this material please log in or register

Register Authorize

Pentoxifylline’s effect on myocardial viability in patients with chronic heart failure according to results of dobutamine stress echocardiography

Sychev A. V.1, Mareev V. Yu.2
1 - Federal State Budgetary Institution, “Russian Cardiology Research and Production Complex” of the RF Ministry of Health Care, 3rd Cherepkovskaya 15a, Moscow 121552
2 - Federal State Budgetary Educational Institution of Higher Professional Education “M. V. Lomonosov Moscow State University”, Lomonosovskyi prospekt, 27B, Moscow 117192

Keywords: dobutamine stress-echocardiography, myocardial viability, pentoxifylline, CHF

DOI: 10.18087/rhfj.2010.2.1334

Actuality. Level of tumor necrosis factor α (TNF-α) and interleukin-6 (IL-6) increases significantly in patients with CHF. Pentoxifylline can inhibit production of TNF-α and thereby reduce its biological effects. Contradictial results of several clinical trials of pentoxifylline use in patients with CHF were the prerequisite for this work. Aim. To study the influence of pentoxifylline (in complex treatment) on myocardial viability, using stress echocardiography in patients with CHF of different etiology. Materials and methods. 40 patients with compensated CHF I–III FC, EF <40 %, were randomized into 2 groups of 20 people (10 patients with CAD and 10 with dilated cardiomyopathy (DCM)). Group I received standard therapy (ACE inhibitors, β-blockers, diuretics), Group II (combined therapy) in addition to standard therapy was prescribed pentoxifylline (daily dose 1200 mg). Dobutamine stress echocardiography was used as a primary method for assessing the influence of pentoxifylline on myocardial viability in patients with CHF. Measurment of soluble receptors for TNF-α I-type level (mediating biological effects of TNF-α) and level of IL-6 was perfomed by ELISA. Control examinations were performed at baseline and in 3 months. Results. During the study none of variables evaluated with stress echocardiography (the number of viable segments, asynergy index, EF increase) changed statistically significantly. Analysis of cytokine levels showed statistically significant decrease of TNF-α receptors level (from 1592 to 1496 pg / ml (p=0.042) in Group II. The level of IL-6 did not change significantly in both groups. Thus, pentoxifylline does not affect basic parameters of myocardial viability in patients with CHF, defined by dobutamine stress echocardiography.
  1. Picano E. Dipyridamole-echocardiography test: historical background and physiologic basis. Eur Heart J. 1989;10 (4):365–376.
  2. Armstrong WF. Stress echocardiography for detection of coronary artery disease. Circulation. 1991;84 (3 Suppl):I43–49.
  3. Bairey CN, Rozanski A, Berman DS. Exercise echocardiography: ready or not? J Am Coll Cardiol. 1988;11 (6):1355–1358.
  4. Picano E. Stress echocardiography. From pathophysiological toy to diagnostic tool. Circulation. 1992;85 (4):1604–1612.
  5. Picano E. Stress echocardiography: a historical perspective. Am J Med. 2003;114 (2):126–130.
  6. Gibbons RJ, Chatterjee K, Daley J. ACC / AHA / ACP-ASIM guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology / American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients With Chronic Stable Angina). J Am Coll Cardiol. 1999;33 (7):2092–2197.
  7. Fox K, Garcia MA, Ardissino D et al. Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J. 2006;27 (11):1341–1381.
  8. Tennant R, Wiggers CJ. The effects of coronary occlusion on myocardial contraction. Am J Physiol. 1935;112 (2):351–361.
  9. Kerber RE, Abboud FM. Echocardiographic detection of regional myocardial infarction: an experimental study. Circulation. 1973;47 (5):997–1005.
  10. Theroux P, Franklin D, Ross J Jr, Kemper WS. Regional myocardial function during acute coronary artery occlusion and its modification by pharmacologic agents in the dog. Circ Res. 1974;35 (6):896–908.
  11. Sugishita Y, Koseki S, Matsuda M et al. Dissociation between regional myocardial dysfunction and ECG changes during myocardial ischemia induced by exercise in patients with angina pectoris. Am Heart J. 1983;106 (1 Pt 1):1–8.
  12. Distante A, Rovai D, Picano E et al. Transient changes in left ventricular mechanics during attacks of Prinzmetal’s angina: an M-mode echocardiographic study. Am Heart J. 1984;107 (3):465–474.
  13. Picano E, Distante A, Masini M et al. Dipyridamole-echocardiography test in effort angina pectoris. Am J Cardiol. 1985;56 (7):452–456.
  14. Piérard LA, De Landsheere CM, Berthe C et al. Identification of viable myocardium by echocardiography during dobutamine infusion in patients with myocardial infarction after thrombolytic therapy: comparison with positron emission tomography. J Am Coll Cardiol. 1990;15 (5):1021–1031.
  15. Picano E, Landi P, Bolognese L et al. Prognostic value of dipyridamole echocardiography early after uncomplicated myocardial infarction: a large-scale, multicenter trial. The EPIC Study Group. Am J Med. 1993;95 (6):608–618.
  16. Picano E, Mathias W Jr, Pingitore A et al. Safety and tolerability of dobu­tamine-atropine stress echocardiography: a prospective, multicentre study. Echo Dobutamine International Cooperative Study Group. Lancet. 1994;344 (8931):1190–1192.
  17. Bax JJ, Poldermans D, Elhendy A et al. Sensitivity, specificity, and predictive accuracies of various noninvasive techniques for detecting hibernating myocardium. Curr Probl Cardiol. 2001;26 (2):147–186.
  18. Allman KC, Shaw LJ, Hachamovitch R et al. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis. J Am Coll Cardiol. 2002 Apr 3;39 (7):1151–1158.
  19. Skudicky D, Bergemann A, Sliwa K et al. Beneficial effects of pentoxifylline in patients with idiopathic dilated cardiomyopathy treated with angiotensin-converting enzyme inhibitors and carvedilol: results of a randomized study. Circulation. 2001;103 (8):1083–1088.
  20. Sliwa K, Woodiwiss A, Kone VN et al. Therapy of ischemic cardiomyopathy with the immunomodulating agent pentoxifylline: results of a randomized study. Circulation. 2004;109 (6):750–755.
  21. Bozkurt B, Kribbs SB, Clubb FJ Jr et al. Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats. Circulation. 1998;97 (14):1382–1391.
  22. Schiller NB, Shah PM, Crawford M et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr. 1989;2 (5):358–367.
  23. Afridi I, Kleiman NS, Raizner AE, Zoghbi WA. Dobutamine echocardio­graphy in myocardial hibernation. Optimal dose and accuracy in predicting recovery of ventricular function after coronary angioplasty. Circulation. 1995;91 (3):663–670.
  24. Sawada SG, Segar DS, Ryan T et al. Catecholamine stress echocardiography. Echocardiography. 1992;9 (2):177–188.
  25. Kalra DK, Zhu X, Ramchandani MK et al. Increased myocardial gene expression of tumor necrosis factor-alpha and nitric oxide synthase-2: a potential mechanism for depressed myocardial function in hibernating myocardium in humans. Circulation. 2002;105 (13):1537–1540.
Sychev A. V., Mareev V. Yu. Pentoxifylline’s effect on myocardial viability in patients with chronic heart failure according to results of dobutamine stress echocardiography. Russian Heart Failure Journal. 2010;11(2):97-102.

To access this material please log in or register

Register Authorize
Ru En